

# Diederik M Somford

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4922472/publications.pdf>

Version: 2024-02-01

68  
papers

3,326  
citations

318942

23  
h-index

162838

57  
g-index

80  
all docs

80  
docs citations

80  
times ranked

4018  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 65-70.	2.0	12
2	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 43-52.	0.9	3
3	The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications. <i>Journal of Urology</i> , 2022, 208, 109-118.	0.2	12
4	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. <i>Drugs - Real World Outcomes</i> , 2022, , 1.	0.7	0
5	Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. <i>ESMO Open</i> , 2022, 7, 100416.	2.0	10
6	Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands. <i>World Journal of Urology</i> , 2022, , 1.	1.2	0
7	Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography. <i>Journal of Personalized Medicine</i> , 2022, 12, 726.	1.1	2
8	Targeting <i>FGFR3</i> alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. <i>Future Oncology</i> , 2022, 18, 2599-2614.	1.1	10
9	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Oncology</i> , 2021, 4, 618-627.	2.6	6
10	Functional and oncological outcomes of salvage cryosurgery for radiorecurrent prostate cancer. <i>BJU International</i> , 2021, 128, 46-56.	1.3	4
11	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796.	1.6	1
12	Optimizing the risk threshold of lymph node involvement for performing extended pelvic lymph node dissection in prostate cancer patients: a cost-effectiveness analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 72.e7-72.e14.	0.8	1
13	The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 871-879.	2.0	8
14	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. <i>Clinical Cancer Research</i> , 2021, 27, 3595-3601.	3.2	53
15	What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1048-1054.	2.0	10
16	Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative. <i>European Urology Open Science</i> , 2021, 26, 18-26.	0.2	4
17	Liquid biopsy reveals <i>KLK3</i> mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021, 15, 2453-2465.	2.1	9
18	Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 667658.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, 4523-4523.	0.8	2
20	Reassessment of Prostate Biopsy Specimens for Patients Referred for Robot-assisted Radical Prostatectomy Rarely Influences Surgical Planning. European Urology Open Science, 2021, 28, 36-42.	0.2	2
21	Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi). European Urology Open Science, 2021, 28, 52-61.	0.2	9
22	Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 60.e1-60.e1.	0.8	4
23	High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry. Journal of Palliative Medicine, 2021, 24, 1789-1797.	0.6	4
24	PD61-02â€¦PREOPERATIVE PSMA PET/CT AS A PREDICTOR OF BIOCHEMICAL PERSISTENCE AND EARLY BIOCHEMICAL RECURRENCE. Journal of Urology, 2021, 206, .	0.2	0
25	Patientsâ€™ perspective on the quality of prostate cancer follow-up care.. Journal of Clinical Oncology, 2021, 39, 175-175.	0.8	0
26	Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer. Theranostics, 2021, 11, 1527-1541.	4.6	25
27	Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer. Nuclear Medicine Communications, 2021, 42, 476-481.	0.5	3
28	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 6279.	1.7	5
29	Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting. European Urology Oncology, 2020, 3, 231-238.	2.6	30
30	Implementation of a decision aid for localized prostate cancer in routine care: A successful implementation strategy. Health Informatics Journal, 2020, 26, 1194-1207.	1.1	9
31	Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative. Journal of Cancer Education, 2020, 35, 1141-1148.	0.6	7
32	Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?. European Urology Oncology, 2020, 3, 216-223.	2.6	35
33	Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 735.e17-735.e25.	0.8	19
34	799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations. Annals of Oncology, 2020, 31, S606.	0.6	0
35	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. Clinical Chemistry, 2020, 66, 842-851.	1.5	25
36	Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncology, 2020, 16, 1371-1384.	1.1	25

#	ARTICLE	IF	CITATIONS
37	Prostate biopsy techniques and pre-biopsy prophylactic measures: variation in current practice patterns in the Netherlands. <i>BMC Urology</i> , 2020, 20, 24.	0.6	7
38	Abstract 1413: Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective observational study. , 2020, , .		0
39	Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial. <i>European Urology Oncology</i> , 2019, 2, 617-624.	2.6	46
40	The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. <i>European Urology</i> , 2019, 75, 582-590.	0.9	188
41	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. <i>European Urology Focus</i> , 2019, 5, 407-415.	1.6	23
42	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 222-229.	1.0	11
43	Incidence and Risk Factors of Postoperative Urinary Retention and Bladder Catheterization in Patients Undergoing Fast-Track Total Joint Arthroplasty: A Prospective Observational Study on 371 Patients. <i>Journal of Arthroplasty</i> , 2018, 33, 1546-1551.	1.5	46
44	Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 122-129.	1.1	41
45	External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients. <i>European Urology Oncology</i> , 2018, 1, 411-417.	2.6	31
46	Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?. <i>European Urology</i> , 2017, 71, 517-531.	0.9	326
47	An <i>Ex Vivo</i> Phantom Validation Study of an MRI-Transrectal Ultrasound Fusion Device for Targeted Prostate Biopsy. <i>Journal of Endourology</i> , 2016, 30, 685-691.	1.1	9
48	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1369-1380.	1.6	74
49	Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. <i>World Journal of Urology</i> , 2015, 33, 1411-1417.	1.2	10
50	Value of 3-T Multiparametric Magnetic Resonance Imaging and Magnetic Resonance-Guided Biopsy for Early Risk Re-stratification in Active Surveillance of Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2014, 49, 165-172.	3.5	83
51	Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection. <i>World Journal of Urology</i> , 2014, 32, 461-467.	1.2	2
52	Re: Markus Graefen, Thorsten Schlomm. Active Surveillance for Low-risk Prostate Cancer: Some Questions Are Answered, but Many Questions Remain. <i>Eur Urol</i> 2013;63:604-5. <i>European Urology</i> , 2013, 64, e65-e66.	0.9	0
53	The Predictive Value of Endorectal 3 Tesla Multiparametric Magnetic Resonance Imaging for Extraprostatic Extension in Patients with Low, Intermediate and High Risk Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 1728-1734.	0.2	177
54	Editorial Comment. <i>Journal of Urology</i> , 2013, 190, 873-873.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Evaluation of Diffusion-Weighted MR Imaging at Inclusion in an Active Surveillance Protocol for Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2013, 48, 152-157.	3.5	63
56	Initial Experience With Identifying High-Grade Prostate Cancer Using Diffusion-Weighted MR Imaging (DWI) in Patients With a Gleason Score $\geq 3 + 3 = 6$ Upon Schematic TRUS-Guided Biopsy. <i>Investigative Radiology</i> , 2012, 47, 153-158.	3.5	65
57	Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy. <i>World Journal of Urology</i> , 2012, 30, 105-110.	1.2	18
58	Value of multimodality MRI and MR-guided biopsy at inclusion in an active surveillance protocol for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 105-105.	0.8	0
59	Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging. <i>Radiology</i> , 2011, 261, 46-66.	3.6	618
60	Relationship between Apparent Diffusion Coefficients at 3.0-T MR Imaging and Gleason Grade in Peripheral Zone Prostate Cancer. <i>Radiology</i> , 2011, 259, 453-461.	3.6	537
61	Magnetic Resonance Imaging Guided Prostate Biopsy in Men With Repeat Negative Biopsies and Increased Prostate Specific Antigen. <i>Journal of Urology</i> , 2010, 183, 520-528.	0.2	344
62	298 VALUE OF 3 TESLA MULTIMODALITY MR GUIDED BIOPSY (MRGB) TO DETECT PROSTATE CANCER IN PATIENTS AFTER AT LEAST TWO PREVIOUS NEGATIVE BIOPSIES AND AN ELEVATED PSA. <i>European Urology Supplements</i> , 2009, 8, 195.	0.1	1
63	828 INTRAPROSTATIC LOCATION OF PROSTATE CANCER IN PATIENTS WITH > 2 NEGATIVE PROSTATE BIOPSY SESSIONS AND AN ELEVATED PSA USING MR GUIDED BIOPSY FOR TUMOUR DETECTION AND LOCATION VALIDATION. <i>European Urology Supplements</i> , 2009, 8, 327.	0.1	1
64	VALUE OF 3 TESLA MULTI-MODALITY DIRECTED MR GUIDED BIOPSY TO DETECT PROSTATE CANCER IN PATIENTS AFTER AT LEAST TWO PREVIOUS NEGATIVE BIOPSIES AND ELEVATED PSA. <i>Journal of Urology</i> , 2009, 181, 706.	0.2	2
65	Diffusion and Perfusion MR Imaging of the Prostate. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2008, 16, 685-695.	0.6	73
66	Influence of Arterial Input Function on Hypoperfusion Volumes Measured With Perfusion-Weighted Imaging. <i>Stroke</i> , 2004, 35, 94-98.	1.0	103
67	Association of early CT abnormalities, infarct size, and apparent diffusion coefficient reduction in acute ischemic stroke. <i>American Journal of Neuroradiology</i> , 2004, 25, 933-8.	1.2	16
68	Proximal and Distal Hyperattenuating Middle Cerebral Artery Signs at CT: Different Prognostic Implications. <i>Radiology</i> , 2002, 223, 667-671.	3.6	45